Plasmapheresis Treatment for Myasthenia Gravis

Slides:



Advertisements
Similar presentations
Myasthenia Gravis Dr. Belal M. Hijji, RN. PhD February 29, 2012.
Advertisements

USE OF STEROIDS IN PATIENTS WITH COPD EXACERBATION Richard C. Walls.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Therapeutic Plasma Exchange for Myasthenia Gravis Clifford Blieden, MD Houston Methodist Hospital Department of Pathology and Genomic Medicine, Division.
Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.
Cahalans-Month-of-Madness/
The Role of Therapeutic Apheresis in Neurological Disorders
ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
This lecture was conducted during the Nephrology Unit Grand Ground by Medical Student rotated under Nephrology Division under the supervision and administration.
Myasthenia Gravis Victor Politi,M.D.
Medical and Surgical Management of MG Brian A. Crum, MD Department of Neurology Mayo Clinic Rochester, MN MGFA National Meeting, St. Louis May, 2010.
Interactive Case Discussion Case 6 Dr Megha S Uppin Asst Prof Dept of Pathology Nizam’s Institute of Medical Sciences Hyderabad.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
Experiences with plasmapheresis in our pediatric dialysis unit L. Koster-Kamphuis, E. Cornelissen, E. Levtchenko, N. van de Kar Dept. of Pediatric Nephrology.
Impact of early surgery vs conventional treatment for infective endocarditis on mortality and embolic events: data from EASE trial Prospective RCT ( );
Intra - Arterial Thrombolysis for acute stroke
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Jeff Kaufhold MD FACP April 2009
Colm Magee, MD, MPH, FRCPI Renal Unit, Beaumont Hospital Nov 2015 Quality and Safety in Therapeutic Plasma Exchange (TPE)
Disorders of the Neuromuscular Junction
Chapter 16 Tolerance and Autoimmunity Dr. Capers.
You Can Never Stop a Biologic
Thrice-Weekly Glatiramer Acetate for Relapsing Forms of Multiple Sclerosis: Findings from the GALA Study Fred D. Lublin, MD Saunders Family Professor of.
Myasthenia Gravis: An inheritable disorder or an acquired auto-immune response Research in Allied Health Jeri Frazier November 1, 2005.
brains&GAINS November 2, a.m. Center For Tomorrow
Assessment and Treatments  History: weakness caused by any precipitating factors ( i.e. infection, emotional upset)  Time of weakness: after repeated.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Nursing management of Myasthenia Gravis
Charles Bell & François Magendie Brit vs
Jennifer Vilarino Period: 5
Pattern Recognition of Myopathic Disorders
Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial
Cryptogenic Sensory Polyneuropathy (CSPN)
Randomized Controlled Trials of Methotrexate & Mycophenolate in MG
Prednisone for MG Richard J. Barohn, MD Gary Gronseth, MD
Advice For Young Investigators in Clinical and Translational Research
CONCLUSION/ CLINICAL IMPLICATIONS REFERENCES/ACKNOWLEDGEMENTS
Plasmapheresis or IVIG for GBS
Mechanism and Treatment of Antibody-Mediated Rejection
HOPE: Heart Outcomes Prevention Evaluation study
Cardiovascular Research Technology Conference (CRT 17)
Neal B, et al. Diabetes Care 2015;38:403–411
Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:
Myasthenia gravis By: Nikki Young.
Diabetic Lumbosacral Radiculoplexopathy DLSRP
Valsartan in Acute Myocardial Infarction Trial Investigators
Setareh Omran, MD Vascular Neurology Fellow
Neuromuscular landmark studies review
Pyridostigmine for MG Richard J. Barohn, MD
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Boceprevir in Treatment Naive SPRINT-2
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)
Results w the CI.
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.
Modified Rankin score 0-2
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
Figure 1 Comparison of miR-150-5p (log scale), prednisone dose (mg), and QMG score between the thymectomy (ETTX) and prednisone groups Comparison of miR-150-5p.
Thymectomy for Myasthenia Gravis? YES!
Figure 1 Neuromuscular junction in myasthenia gravis (MG)
Figure 2 NMDAR-Ab levels, clinical syndromes, and therapy in 8 informative patients with white matter syndromes in association with NMDAR-Ab NMDAR-Ab levels,
Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical.
Corticosteroids in the ICU
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
History of Neurology KARL LASHLEY PHD ( ) March 9, 2018
Myasthenia Gravis By: Cheryl Hamilton.
Telaprevir + Peginterferon + Ribavirin for GT1 PROVE1 Study
IVIg Therapy. IVIg Therapy What are Immunoglobulins? Immunoglobulins, also known as antibodies, are proteins that bind specifically to antigens Immunoglobulin.
Presentation transcript:

Plasmapheresis Treatment for Myasthenia Gravis www.rrnmf.com Richard J. Barohn, MD Chair, Department of Neurology Gertrude and Dewey Ziegler Professor of Neurology University Distinguished Professor Vice Chancellor for Research University of Kansas Medical Center Kansas City, KS

Plasmapheresis for MG Directly removes humoral factors such as autoantibodies, immune complexes, complement and other nonspecific inflammatory mediators Remove 3-6 liters of plasma over several hours. Replace with albumin or purified protein fraction (PPF). Indications for MG: crises pre-thymectomy severe MG (not in crises) when initiating or increasing oral immunosuppressive drugs chronic Rx

Early Reports of Plasmapheresis for MG Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med 297:1134, 1977 5 pts Newsom-Davis J, Pinching AJ, Vincent A, Wilson SG: Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. Neurology 28(3):266-272, 1978 8 pts Newsom-Davis J, Wilson SG, Vincent A et al: Long term effects of repeated plasma exchange in myasthenia gravis. Lancet 1:464, 1979 13 pts Olarte MR, Schoenfeldt RS, Penn AS et al: Effect of plasmapheresis in myasthenia gravis, 1978-1980. Ann NY Acad Sci 377:725, 1981 21 pts Keesey J, Buffkin D, Kebo D, et al: Plasma exchange alone as therapy for myasthenia gravis. Ann NY Acad Sci 377:729, 1981 3 pts

MG: Plasma Exchange First successful reports in late 1970’s Antibody levels fall but response does not correlate with starting titers Improvement occurs in days Improvement may be seen even if serum antibody is absent All small case series No randomized trial done against placebo or no PE

Plasmaphresis vs. IVIG For MG Gajdos et al, Ann Neurol 1997 87 pts with MG exacerbation Randomized: 3 PT vs. 3 or 5 IVIG 0.4 gm/kg Endpoint – Myasthenic muscular score day 15 Results – Equal improvements with both Rx: PE + 18 pts IVIG + 15.5 points p = 0.65 Fewer side effects with IVIG (1) vs. PE (8)

Comparison of IVIg & Plex in MG Barth, et al Neurology 2011;76 84 pts to IVIg 1g/kg/d x 2 days Or PE x 5 QMG > 10.5 and “worsening” Improved: 69% IVIg and 65% PE Conc: IVIg & PE both effective Rx

Pheresis for MG: Recommendation: Level U (Unknown) Neurology 2011;76:294-300

Plasmapheresis Rx for MG HOW MUCH? 4-6 Exchanges of 3-5 Liters of Plasma Can be Daily or QOD However, No Exact Science For # Exchanges or Amount Removed in MG Often Depends on How Pt Tolerates PE and How Much Can Be Removed

Plasmapheresis Rx for MG LIMITATIONS Trained technician Equipment IV Access - Often Requires Large Double-Lumen Catheter Complications: Pneumothorax, Hypotension, Sepsis, Pulmonary Embolism Expensive Benefit Lasts Several Weeks

Plasmapheresis: The Problem of Access Periph IV hard to access Chron IJ line – 1 mo to 12 mo infection Ports We tried Vortex Dx Can’t take pressure AV fistulas Clot Cosmetic

A-V Fistulas for Pheresis